ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 25870596

Modulation of CD44 Activity by A6-Peptide.

Finlayson M. Front Immunol, 2015. Cited by 49 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Modulation of CD44 Activity by A6-Peptide. Papers, record 25870596. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/25870596

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Modulation of CD44 Activity by A6-Peptide.
PubMed
Journal
Front Immunol
PubMed
Year
2015
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
49
iCite
Relative citation ratio, by iCite
1.63
iCite
Revised in PubMed
2023-11-04
PubMed

Authors1

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Finlayson MMalcolm

Source PubMed

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References72

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
116,023,182A6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: a phase I trial.Gynecol Oncol2005https://conductscience.org/library/papers/16023182PubMed
220,501,854Breast cancer dormancy can be maintained by small numbers of micrometastases.Cancer Res2010https://conductscience.org/library/papers/20501854PubMed
312,928,429Hyaluronan recognition mode of CD44 revealed by cross-saturation and chemical shift perturbation experiments.J Biol Chem2003https://conductscience.org/library/papers/12928429PubMed
419,633,292
Hyaluronan-CD44 interaction with protein kinase C(epsilon) promotes oncogenic signaling by the stem cell marker Nanog and the Production of microRNA-21, leading to down-regulation of the tumor suppressor protein PDCD4, anti-apoptosis, and chemotherapy resistance in breast tumor cells.
J Biol Chem2009https://conductscience.org/library/papers/19633292PubMed
519,773,544A CD44v6 peptide reveals a role of CD44 in VEGFR-2 signaling and angiogenesis.Blood2009https://conductscience.org/library/papers/19773544PubMed
617,389,513Hepatocyte growth factor/scatter factor promotes retinal angiogenesis through increased urokinase expression.Invest Ophthalmol Vis Sci2007https://conductscience.org/library/papers/17389513PubMed
716,882,693Activation of urokinase receptor by a novel interaction between the connecting peptide region of urokinase and alpha v beta 5 integrin.J Cell Sci2006https://conductscience.org/library/papers/16882693PubMed
819,174,187Rheostatic signaling by CD44 and hyaluronan.Cell Signal2009https://conductscience.org/library/papers/19174187PubMed
912,547,719A urokinase-derived peptide (A6) increases survival of mice bearing orthotopically grown prostate cancer and reduces lymph node metastasis.Am J Pathol2003https://conductscience.org/library/papers/12547719PubMed
1018,559,877A peptide inhibitor of the urokinase/urokinase receptor system inhibits alteration of the blood-retinal barrier in diabetes.FASEB J2008https://conductscience.org/library/papers/18559877PubMed

1 to 10 of 72

See all 72 references

Cited by25

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 49 citations.

PMIDTitleJournalYearIn PapersSource
42,552,379Multifaceted roles of CD44 in cancer progression and targeted therapeutic strategies.Exp Mol Med2026https://conductscience.org/library/papers/42552379PubMed
41,916,275Pre-existing cell states predict resistance to multiple treatments.Cell Genom2026https://conductscience.org/library/papers/41916275PubMed
41,440,277Digging into the Solubility Factor in Cancer Diagnosis: A Case of Soluble CD44 Protein.Biosensors (Basel)2025https://conductscience.org/library/papers/41440277PubMed
41,154,366The Urokinase-Type Plasminogen Activator Receptor (uPAR) as a Mediator of Physiological and Pathological Processes: Potential Therapeutic Strategies.Cancers (Basel)2025https://conductscience.org/library/papers/41154366PubMed
40,611,437Regenerative Hair Pigmentation via Skin Organoids: Adaptive Patterning Mediated by Collagen VI and Semaphorin 3C.Adv Sci (Weinh)2025https://conductscience.org/library/papers/40611437PubMed
40,176,316Peptide-Modified Lipid Nanoparticles Boost the Antitumor Efficacy of RNA Therapeutics.ACS Nano2025https://conductscience.org/library/papers/40176316PubMed
40,083,943Unveiling the potential of biomechanics in pioneering innovative strategies for cancer therapy.Theranostics2025https://conductscience.org/library/papers/40083943PubMed
40,032,983MRI radiomics based on machine learning in high-grade gliomas as a promising tool for prediction of CD44 expression and overall survival.Sci Rep2025https://conductscience.org/library/papers/40032983PubMed
39,901,621Breaking barriers: Smart vaccine platforms for cancer immunomodulation.Cancer Commun (Lond)2025https://conductscience.org/library/papers/39901621PubMed
39,796,700Tumor Cell Survival Factors and Angiogenesis in Chronic Lymphocytic Leukemia: How Hot Is the Link?Cancers (Basel)2024https://conductscience.org/library/papers/39796700PubMed

1 to 10 of 25

See all 25 cited by

Genes18

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ABCB15,243PubTator's text mininghttps://conductscience.org/library/genes/5243NCBI Gene
AKT1207PubTator's text mininghttps://conductscience.org/library/genes/207NCBI Gene
CD44960PubTator's text mininghttps://conductscience.org/library/genes/960NCBI Gene
F22,147PubTator's text mininghttps://conductscience.org/library/genes/2147NCBI Gene
FGB2,244PubTator's text mininghttps://conductscience.org/library/genes/2244NCBI Gene
HGF3,082PubTator's text mininghttps://conductscience.org/library/genes/3082NCBI Gene
MAPK15,594PubTator's text mininghttps://conductscience.org/library/genes/5594NCBI Gene
MMP34,314PubTator's text mininghttps://conductscience.org/library/genes/4314NCBI Gene
MMP74,316PubTator's text mininghttps://conductscience.org/library/genes/4316NCBI Gene
MMP94,318PubTator's text mininghttps://conductscience.org/library/genes/4318NCBI Gene

1 to 10 of 18

See all 18 genes

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/25870596

GET https://conductscience.org/api/papers/v1/25870596/references?page=2

API referenceFor AI assistants